BC Extra | Jul 17, 2019
Company News

July 17 Company Quick Takes: FDA approves Merck antibiotic combo; plus PureTech, Inovio, BiomX

FDA approves Merck's antibiotic combo  FDA approved Merck's Recarbrio imipenem/cilastatin/relebactam antibacterial to treat adults with complicated urinary tract infections (cUTIs) and complicated intra-abdominal infections (cIAIs). Unlike most of its peers, Merck & Co. Inc. (NYSE:MRK)...
BC Week In Review | Feb 22, 2019
Financial News

BiomX raises $32M series B to bring first two therapies to clinic

Phage therapy company BiomX Ltd. (Ness Ziona, Israel) raised a $32 million series B round on Feb. 20 that will take its lead candidate, acne therapy BX001, into the clinic within the next few months....
BC Extra | Feb 20, 2019
Financial News

BiomX raises $32M series B to bring first two therapies to clinic

Phage therapy company BiomX Ltd. (Ness Ziona, Israel) raised a $32 million series B round on Wednesday that will take its lead candidate, acne therapy BX001, into the clinic within the next few months. The...
BC Week In Review | Dec 22, 2017
Company News

BiomX acquires microbiome company RondinX

BiomX Ltd. (Ness Ziona, Israel) acquired fellow microbiome company RondinX (Tel Aviv, Israel), including its computational discovery platform. BiomX said it also gains a pipeline of undisclosed microbial targets that are being validated to treat...
BC Extra | Dec 19, 2017
Company News

BiomX acquires microbiome company RondinX

BiomX Ltd. (Ness Ziona, Israel) said it acquired fellow microbiome company RondinX (Tel Aviv, Israel), including its computational discovery platform. BiomX said it also gains a pipeline of undisclosed microbial targets that are being validated...
BioCentury | May 19, 2017
Finance

BiomX’s balance

After identifying a handful of novel bacterial targets and bacteriophage candidates, BiomX Ltd. was able to attract $24 million in series A funding from some of industry's most active microbiome players. OrbiMed Advisors, the Johnson...
BC Extra | May 15, 2017
Financial News

BiomX raises $24M series A round

Microbiome play BiomX Ltd. (Ness Ziona, Israel) raised $24 million in a series A round led by OrbiMed, the Johnson & Johnson Innovation - JJDC Inc. unit of Johnson & Johnson (NYSE:JNJ), and Takeda Ventures. Also...
Items per page:
1 - 7 of 7